Claims for Patent: 10,485,796
✉ Email this page to a colleague
Summary for Patent: 10,485,796
Title: | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment |
Abstract: | The present invention provides, inter alia, a composition containing a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein. |
Inventor(s): | Saha; Saurabh (Wellesley Hills, MA), Zhang; Linping (Lexington, MA), Zhang; Xiaoyan Michelle (Lexington, MA) |
Assignee: | BIOMED VALLEY DISCOVERIES, INC. (Kansas City, MO) |
Application Number: | 15/809,759 |
Patent Claims: | 1. A method for treating or ameliorating the effects of cancer in a subject comprising administering to the subject an effective amount of a first agent, wherein the first
agent is a selective PI3K.gamma. inhibitor or pharmaceutically acceptable salt thereof, and a second agent, wherein the second agent is an immune checkpoint inhibitor.
2. The method according to claim 1, wherein the immune checkpoint inhibitor is selected from a group consisting of an anti-PD-1 antibody, an anti PD-L1 antibody, an anti-CTLA-4 antibody, and combinations thereof. 3. The method according to claim 1, wherein the immune checkpoint inhibitor is selected from a group consisting of nivolumab (Bristol-Myers Squibb), pembrolizumab (Merck), pidilizumab (Curetech), AMP-224 (GlaxoSmithKline/Amplimmune), MPDL3280A (Roche), MDX-1105 (Medarex, Inc./Bristol Myer Squibb), MEDI-4736 (Medimmune/AstraZeneca), arelumab (Merck Serono), ipilimumab (YERVOY, (Bristol-Myers Squibb), tremelimumab (Pfizer), pidilizumab (CureTech, Ltd.), IMP321 (Immutep S.A.), MGA271 (Macrogenics), BMS-986016 (Bristol-Meyers Squibb), lirilumab (Bristol-Myers Squibb), urelumab (Bristol-Meyers Squibb), PF-05082566 (Pfizer), IPH2101 (Innate Pharma/Bristol-Myers Squibb), MEDI-6469 (MedImmune/AZ), CP-870,893 (Genentech), Mogamulizumab (Kyowa Hakko Kirin), Varlilumab (CellDex Therapeutics), Avelumab (EMD Serono), Galiximab (Biogen Idec), AMP-514 (Amplimmune/AZ), AUNP 12 (Aurigene and Pierre Fabre), Indoximod (NewLink Genetics), NLG-919 (NewLink Genetics), INCB024360 (Incyte) and combinations thereof. 4. The method according to claim 1, wherein the first and second agents are administered as a single unit dose. 5. The method according to claim 1, wherein the first and second agents are co-administered. 6. The method according to claim 1, wherein the first agent is administered prior to the second agent. 7. The method according to claim 1, wherein the second agent is administered prior to the first agent. 8. The method according to claim 1, wherein the administration of the first and second agents to the subject provides a synergistic effect in the treatment of the cancer. 9. The method according to claim 1, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, hepatocellular carcinoma, leukemia, lung cancer, lymphoma, melanoma, multiple myeloma, neuroblastoma, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cell carcinoma, rhabdoid cancer, sarcomas, and urinary track cancer. 10. The method according to claim 1, wherein the cancer is selected from the group consisting of bladder cancer, colon cancer, lung cancer, lymphoma, and pancreatic cancer. 11. The method according to claim 1, wherein the subject is a mammal. 12. The method according to claim 11, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals. 13. The method according to claim 12, wherein the mammal is a human. 14. The method according to claim 1, wherein the selective PI3K.gamma. inhibitor is effective to reduce PI3K.gamma. kinase activity on one or more of the following protein substrates: ABL, ALK, AMPK.alpha.1, ASK1, AXL, BLK, BTK, CaMKII.beta., CDK1/CycB, CDEK5/P35, CHK1, CK1.gamma.1, cKIT, cRAP, cSRC, EGFR, EphB4, FES, FGFR3, Flt1 (VEGFR1), FYN, HIPK2, IGF-1R, IKK.alpha., IR, JNK1.alpha.,1, LCK, LYN, MAPK1, MEK1, MKK6, MKK7.beta., MLCK, MSK1, MST2, mTOR, NEK2, PAK2, PDGFR.alpha., Pim-2, PKC.beta.II, PKC.sub.1, PKC.theta., PRAK, PRK2, RET, RIPK2 (RICK), ROCK II, ROS (KROS), RSK3, SAPK2.beta., SGK, TAK1, TIE2, TrkA, and ZAP70. |
Details for Patent 10,485,796
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2035-06-29 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-06-29 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-06-29 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-06-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.